Ugur Sahin, the co-founder and CEO of BioNTech SE (BNTX), sold $119.58 million worth of the Germany-based biotechnology ...

BioNTech CEO and co-founder Professor Ugur Sahin said: "We believe that BNT327/PM8002 has the potential to set a new standard of care in multiple oncology indications, surpassing traditional check ...

Run by husband-and-wife team Ugur Sahin and his wife Ozlem Tureci, BioNTech wanted to use the technology to create individualised cancer therapies. Matthias Kromayer, a general partner at the ...

Commenting on the acquisition, Dr. Ugur Sahin, CEO of BioNTech said, "We are excited to welcome Biotheus and its innovative technology to BioNTech,". He further added, "This acquisition enhances ...

“We see a significant opportunity at the intersection of AI and immunology by computational design of new precision immunotherapies,” said BioNTech chief executive Ugur Sahin. “This ...

BioNTech co-founder Ugur Sahin said the company believes the active ingredient has the potential to set a new standard of treatment in certain cancers. Several studies with the active ingredient ...

BioNTech said that with Pfizer ... and have made numerous clinical advances,” said Chief Executive Ugur Sahin. “Today, our oncology pipeline encompasses multiple candidates in mid- and ...